UBS Group
IMPL

UBS Group’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

UBS Group’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,445
Closed -$621 – 10332
2023
Q3 		$621 Buy
1,445
+137
+10% +$132 ﹤0.01% 8372
2023
Q2 		$1.66K Hold
1,308
– – ﹤0.01% 7877
2023
Q1 		$1.83K Sell
1,308
-435
-25% -$1.04K ﹤0.01% 8637
2022
Q4 		$6.54K Buy
1,743
+435
+33% +$1.58K ﹤0.01% 9023
2022
Q3 		$6K Hold
1,308
– – ﹤0.01% 9115
2022
Q2 		$12K Sell
1,308
-650
-33% -$4.75K ﹤0.01% 7712
2022
Q1 		$13K Sell
1,958
-13,709
-88% -$104K ﹤0.01% 8101
2021
Q4 		$135K Buy
15,667
+9,136
+140% +$91.2K ﹤0.01% 6025
2021
Q3 		$80K Buy
6,531
+5,361
+458% +$77.8K ﹤0.01% 5991
2021
Q2 		$10K Buy
+1,170
New +$14K ﹤0.01% 8073

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

UBS Group's IMPL Position: Q4 2023 in Review

UBS Group sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 1,445 shares — an estimated $621 sold.

UBS Group first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $135K in Q4 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • UBS Group reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 1,445 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $621.
  • UBS Group first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • UBS Group's Impel Pharmaceuticals Inc. Common Stock position peaked at $135K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.